Axsome Therapeutics, Inc.(AXSM)Earnings, Financials & Key RatiosAxsome Therapeutics, Inc. (AXSM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while revenue growth is impressive, the company's current ratio has tightened to 1.39, suggesting that liquidity constraints may necessitate further dilutive financing to sustain operations.
Axsome Therapeutics, Inc. (AXSM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Axsome Therapeutics, Inc. (AXSM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.26vs $0.85-48.2% | $189Mvs $191M-0.8% |
| Q1 2026 | Feb 23, 2026 | $0.71vs $0.70-1.4% | $195Mvs $193M+0.7% |
| Q4 2025 | Nov 3, 2025 | $0.94vs $0.82-14.6% | $171Mvs $191M-10.6% |
| Q3 2025 | Aug 4, 2025 | $0.92vs $1.00+8.0% | $150Mvs $140M+7.2% |
Recent stock market news and headlines for Axsome Therapeutics, Inc. (AXSM)
Axsome specializes in central nervous system disorders, including depression, migraine, and fibromyalgia. Axsome's Auvelity recently won approval to treat agitation associated with Alzheimer's disease.
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inbox, subscribe here.
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD).
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month. “Nearly everyone knows brain health is important, but many people aren't sure what steps to take to protect it,” said Wendy Vizek, Senior Vice President, Community Engagement and Field Operations at the Alzheimer's Association.
All three could become highly prominent biotech companies within 10 years.
Key metrics vs top competitors for Axsome Therapeutics, Inc. (AXSM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $242.60 | $12.48B | -65.92 | 65.55% | -28.69% | -252.11% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — | |
| $5.69 | $2.51B | 10.16 | 50.54% | 8.99% | 14.24% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — |
Axsome Therapeutics, Inc. (AXSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Axsome Therapeutics, Inc. (AXSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Apr 30, 2026·SEC
Apr 1, 2026·SEC
Get notified when AXSM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Axsome Therapeutics, Inc. (AXSM) stock FAQ — growth, dividends, profitability & financials explained
Axsome Therapeutics, Inc. (AXSM) reported $708.2M in revenue for fiscal year 2025.
Axsome Therapeutics, Inc. (AXSM) grew revenue by 65.5% over the past year. This is strong growth.
Axsome Therapeutics, Inc. (AXSM) reported a net loss of $188.3M for fiscal year 2025.
Axsome Therapeutics, Inc. (AXSM) has a return on equity (ROE) of -252.1%. Negative ROE indicates the company is unprofitable.
Axsome Therapeutics, Inc. (AXSM) had negative free cash flow of $71.0M in fiscal year 2025, likely due to heavy capital investments.
